Erlocip otherwise called Erlotinib is a doctor prescribed medication utilized as a part of the treatment of non-little cell lung disease and pancreatic malignancy. It interferes with the protein epidermal development factor, keeping it from enacting catalysts which is required in certain growth cells to develop and duplicate.
Manufacturer : Cipla Ltd.
Additional Information :
Prescribed Dose : NSCLC
EGFR transformation testing must be performed before start of ERLOCIP Tablets treatment in chemo-guileless patients with cutting edge or metastatic NSCLC.
The suggested day by day measurement of ERLOCIP Tablets for NSCLC is 150 mg gone up against an unfilled stomach no less than 1 hour prior or 2 hours after the ingestion of nourishment. Treatment should proceed until malady movement or inadmissible danger happens. There is no confirmation that treatment past movement is advantageous.
Prescribed Dose : Pancreatic Cancer
Most regular reactions are Nausea, Vomiting, Fatigue, Breathing trouble, Abdominal agony, Edema, Weight misfortune, Loss of craving, Anemia, Infection, Bone torment, Constipation, Diarrhea, Fever, Stomatitis (Inflammation of the mouth), Rash.
PACK SIZE : Pack of 30 tablets